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Oestrogen receptors (ER) are encoded by the ER-a and ER-b genes
(Kuiper et al, 1996; Mosselman et al, 1996). These two receptors
share about 95% homology in the DNA binding domain and 55%
homology in the ligand binding domain, bind to a consensus
oestrogen response element (ERE) (Tremblay et al, 1997) and
have similar ligand binding properties (Kuiper et al, 1997). The
reverse transcription polymerase chain reaction (RT-PCR) has
revealed that ER-b is expressed at high levels in the prostate and
ovary (Kuiper et al, 1996; Mosselman et al, 1996), and at moderate
levels in many other tissues, including the testis and the uterus,
parts of which also seem to express ER-b (Kuiper et al, 1997).
Oestrogen promotes the progression of breast cancer. The presence
of ER-a and ER-b mRNA in both normal and neoplastic human
breast tissues has been reported (Dotzlaw et al, 1997).
Furthermore, the relative expression of ER-a and ER-b mRNA
differs between normal human breast tissues and concurrently
matched ER-positive breast tumours (Leygue et al, 1998),
suggesting that ER-a and ER-b expression is functionally altered
during breast tumorigenesis. Although the two receptors are often
coexpressed in breast cancer, the levels of ER-b mRNA appear to
vary among breast tumours (Dotzlaw et al, 1997), raising the ques-
tion as to whether ER-b expression correlates with prognostic or
endocrinological markers. The expression of ER-b mRNA is
inversely correlated with progesterone receptor (PR) status,
suggesting that ER-b expression is regulated by progestins
(Dotzlaw et al, 1999). However, no specific data regarding ER- b
distribution in endometrial cancer have been published. Therefore,
we assessed the relative expression of ER-a and ER-b mRNAs in
endometrial cancers, to determine whether or not the expression of
these receptors is altered during endometrial tumorigenesis. 
MATERIAL AND METHODS 
Tissues and RNA extraction 
We examined samples of 35 endometrial cancers, 1 of complex
hyperplasia and 1 normal endometrium in the secretory phase
obtained with consent from patients who were treated at the
Gunma University Hospital, Department of Obstetrics and Gynae-
cology. Samples were immediately frozen in liquid nitrogen and
stored at –80˚C. No chemotherapy or radiation therapies were
performed prior to tumour excision. Surgically resected tissues
were sampled for histopathological diagnosis. Clinical stage and
histological classification were established according to the
International Federation of Gynaecology and Obstetrics (FIGO)
1988 criteria. Myometrial invasion was classified into 7 grades.
Grade 0 indicates a lack of myometrial invasion. Depth of myome-
trial invasion was measured microscopically and categorized from
grades 1/6 to 6/6, 6/6 means carcinoma reached the serosa. Details
are presented in Tables 1 and 2. Total RNA was extracted from
frozen tissue sections using the GLASS MAX RNA Micro-
isolation Spin Cartridge System (Gibco/BRL, Grand Island, NY)
according to the manufacturer’s instructions. 
Primers and RT-PCR conditions 
Total RNA (1 mg) was reverse transcribed in 20 ml of reaction mix
for 59 min at 42˚C, then for 15 min at 70˚C. The reaction mix
contained 50 units of Moloney murine leukaemia virus reverse
transcriptase (Perkin Elmer, Foster City, CA), 0.8 mM dNTPs
(Perkin Elmer), 20 units of RNase inhibitor (Perkin Elmer), 10 mM
Tris-HCl (pH8.3), 50 mM KCl, 1.5 mM MgCl2 and 2.5 mM
random hexamers (Perkin Elmer). To determine the relative
expression of ERa and ERb mRNA within individual samples,
two sets of primers were added to each reaction and both ERa and
ERb cDNAs were co-amplified. Reverse transcription reaction 
(3  mg) was amplified by PCR in a final volume of 25 ml, containing
1 unit of Ampli Taq Gold (Perkin Elmer), 10 mM Tris-HCl (pH
8.3), 50 mM KCl, 1.5 mM MgCl2, 0.2 mM dNTPs, and 2 mM of
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followed by 30 cycles at 94˚C for 30 sec and 72˚C for 3 min and an
extension step at 72˚C 5 min. Under these conditions, PCR prod-
ucts were generated within a linear range. Primers used to amplify 
ER-a were: (sense) 5¢-CTGGCTACATCATCTCGGTTCCGCA-3¢
(nucleotides 1577~1601); (antisense) 5¢-TCAGGCCTGCCTTG-
GCCATCAGGT-3¢  (nucleotides 1755~1778), generating an
amplified product of 202 bp. For ER-b, primer sequences were:
(sense) 5¢- GCGCTCAATTGACCACCCCGGCAA-3¢ (nucleotide
894~927); (antisense) 5¢-GCATCGGTCACGGCGTTCAGCAAG-
3¢ (nucleotide 1143~1166), generating an amplified product of
273 bp. The ubiquitously expressed GAPDH cDNA was amplified
in parallel, to prove that used RNAs were not degraded. 
PCR products were subcloned into the pGEM-T Easy vector
(Promega, Madison, WI) and sequenced using a cycle sequencing
kit (Takara Shuzo; Shiga, Japan). 
Multiplex PCR validation 
Two tumours (T1 and T2) were used to validate a multiplex RT-
PCR that was designed to determine the relative expression of 
ER-b: ER-a. T1 expressed medium ER-b/high ER-a mRNA
levels, on the other hand, T2 expressed low ER-b/high ER-a
mRNA levels. 6 cDNA preparations were prepared containing
varying percentages of T1 and T2 cDNA by mixing 5, 4, 3, 2, 1
and 0 ml of T1 cDNA with 0, 1, 2, 3, 4 and 5 ml of T2 cDNA (100,
80, 60, 40, 20 and 0% T1 cDNA, respectively). The two receptor
subtypes were coamplified in 3 ml of cDNA preparation as
described above. PCR products were separated on 1.8% Metaphor
agarose gels (FMC Bio Products; Rockland, USA) and visualized
by ethidium bromide staining under UV illumination. 
Quantitation and statistical analysis 
To compare ER-b mRNA expression relative to that of ER-a
mRNAs, ER-a and ER-b cDNA were coamplified as described
above. Images were captured under UV transillumination on type
667 film (Polaroid Co, Cambridge, MA) and signals were quanti-
fied using BAS-2000 imaging analyser (Fuji Photo Film Co,
Tokyo Japan). Statistical analysis was performed using the Stat
Flex for Windows (Artech Inc, Osaka, Japan). Multiple regression
method was used to analyse the association between the b:a ratio
and clinical factors including age, tumour grade, clinical stage and
myometrial invasion. 
Western blot analysis 
Of 37 endometrial tissue samples, 34 were analysed by Western
blotting. The samples were homogenized in 1 ´ SDS buffer (2%
SDS, 100 mM DTT and 60 mM Tris-HCl pH 6.8). Then, the
preparations were boiled for 5 min, and passed through a 26G
needle with a 1 ml syringe. After monitoring at OD 280/260, they
were diluted with 1 ´ SDS buffer, and 0.4 units (OD280 = 1 unit)
of each sample was applied to SDS-PAGE. Gels were soaked in
transfer buffer (48 mM Tris-HCl, 30 mM glycine and 20%
methanol, pH 9.2) and proteins were transferred to nitrocellulose
membranes (Hybond ECL, Buckinghamshire, England). Immuno-
blotting was performed using anti-ER-a, anti-ER- b, anti-PR
(Santa Cruz Biotechnology; Santa Cruz, CA) and anti-b-actin
(SIGMA; Japan). Signals were developed using ECL Western
blotting detection reagents (Amersham Pharmacia Biotech UK
Limited). 
RESULTS 
Multiplex PCR validation 
The relative expression of ER-a and ER-b mRNA within indi-
vidual samples was determined using a multiplex PCR assay. Two
sets of primers were added to each PCR mixture and both ER-a
and ER-b were amplified in a single tube. To determine whether or
not the results obtained from this assay accurately reflected the
initial ER-b:ER-a ratio, a preliminary multiplex PCR was
performed on tumours T1 and T2. Tumour T1 expressed medium
ER-b/high ER-a mRNA levels, whereas T2 expressed low ER-b/
high ER-a mRNA levels. As shown in Figure 1A, the PCR signal
corresponding to ER-b decreased with decreasing input of T2
cDNA, and the ER-a signal increased with increasing input of T1
cDNA. The ER-b:ER-a ratio signals were plotted as a function of
the percentage of T1 cDNA input. The ER-b:ER-a ratio increased
in a linear fashion as the ER-b input increased. Multiplex PCR
under these conditions showed a dose related increase until the
relative expression of ER-b and ER-a was <0.5 (Figure 1B). 
Expression of ER-a and ER-b mRNAs in human
endometrial cancer tissues, and association with
clinical information 
35 endometrial cancer samples, 1 of complex hyperplasia and 1
normal endometrium were analysed and the expression of both
ER-a and ER-b was compared by multiplex PCR (Figure 2). The
202 bp and 273 bp DNA fragments from a tumour sample that
emitted intense ER-a and ER-b signals were subcloned and
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Table 1 Pathologic details of endometrial cancers used in this study 
Clinical parameters No. 
Patients Total no. in study 36 
Mean age (range) 56 (36~81) 
<50 years 10 
^50 years 26 
Tumour histology endometrioid 32 
clear cell 1 
adenosquamous 1 
serous 1 
complex hyperplasia 1 
Tumour grade Grade 1 19 
Grade 2 9 
Grade 3 4 
Others 4 
Myometrial invasion 0 1 
1/6 19 
2/6 7 
3/6 3 
4/6 2 
5/6 1 
6/6 3 
Clinical stage Ia 0 
b 22 
c3  
IIa 4 
b2  
IIIa 2 
b0  
c1  
IV 1 sequenced. The tumour sequence was identical to that published
for human ER-a and ER-b (Mosselman et al, 1996). ER-a was
expressed constantly in all samples, whereas ER-b was expressed
to varying degrees (Figure 2B). An ER-b:ER-a ratio of >0.5 was
found in only one sample in the present study (Figure 2A). To
determine whether or not ER subtype coexpression in endometrial
cancers is associated with clinical parameters, we examined
multiple regression analysis. Only myometrial invasion showed 
a significant correlation with the ER-b:ER-a ratio (r = 0.54, 
P = 0.0007) (Table 3). Figure 3 shows the correlation between the
ER-b:ER-a ratio and depth of myometrial invasion. Spearman
rank correlation test determined that the correlate coefficient was
0.786 (P < 0.0001). In one normal endometrium, the ER-b:ER-a
ratio was in the medium range (0.145). 
Western blotting analysis 
We examined the status of ER-a and ER-b protein by Western
blotting in the 34 endometrial cancer tissue samples. The represen-
tative pattern of Western blotting was shown in Figure 2C. The
relative expression of ER-b and ER-a protein was well correlated
with analysis of mRNA. Among the 7 cases with severe myo-
metrial invasion (depth ³ 3/6), which expressed high ER-b:ER-b
mRNA ratio (b/a ratio ³ 0.16), 6 cases expressed ER-b protein
relatively more strongly than ER-b protein (No. 6, 10, 17, 19, 23
and 30). Additionally, we analysed progesterone receptor (PR)
protein expression, as some investigators have reported that
expression of the progesterone receptor is related to good prog-
nosis. PR protein was expressed in all endometrial cancer tissues
to varying degrees, and was not correlated with depth of myome-
trial invasion (Figure 2C). There appeared to be no correlation
between the PR protein expression pattern and clinicopathological
parameters. 
DISCUSSION 
Oestrogens are important mitogenic stimulants in endometrial and
breast cancer in addition to playing important physiological roles
in normal tissues. Oestrogen acts by binding to its specific recep-
tors, ER-a and ER-b, although the physiological roles of these
receptors have not been clearly distinguished. Dotzlaw et al (1997)
showed that ER-a expression does not correlate with that of ER-a,
ER-b expression and myometrial invasion in human endometrial cancer 547
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Table 2 Clinical characteristics of patients in this study 
Case Age Histology Clinical Histological  Myometrial  Surgical  procedure Adjuvant  Outcome b/a ratio 
stage grade invasion therapy ´100 
1 58 endometrioid Ib G1 2/6 mRH,BSO,PLA CAP2 death(3mo)*1 7.7 
2 50 endometioid Ib G1 1/6 mRH,BSO,PLA dfs(2y7mo) 0.0 
3 81 endometrioid IIa G3 2/6 ATH,BSO death(2y5mo) 2.5 
4 48 endometrioid IIa G2 1/6 ARH,BSO,PLA dfs(2y9mo) 7.6 
5 58 endometrioid Ib G3 1/6 mRH,BSO,PLA CAP3 dfs(2y5mo) 11.0 
6 80 clear cell Ic 5/6 ATH,BSO dfs(2y8mo) 47 
7 44 adenosquamous Ib 1/6 mRH,BSO,PLA,PAN dfs(2y6mo) 6.8 
8 60 endometrioid Ib G3 1/6 ATH,BSO CAP3 dfs(2y8mo) 0.0 
9 51 endometrioid Ib G2 1/6 ATH,BSO CAP5 dfs(2y4mo) 6.3 
10 55 endometrioid Ib G1 3/6 mRH,BSO,PLA dfs(2y2mo) 31.5 
11 47 endometrioid Ib G1 1/6 mRH,BSO,PLA dfs(2y1mo) 1.5 
12 74 serous adeno IIIc 1/6 mRH,BSO,PLA radiation death(1y6mo) 6.0 
13 52 endometrioid IIb G1 2/6 mRH,BSO,PLA dfs(2y0mo) 5.6 
14 45 endometrioid IIa G1 2/6 mRH,BSO,PLA CAP3 dfs(1y8mo) 12.2 
15 36 endometrioid Ib G1 2/6 ATH,BSO death(POD6)*2 4.3 
16 46 endometrioid Ib G1 1/6 mRH,BSO,PLA CAP3 dfs(1y7mo) 8.2 
17 69 endometrioid IIa G2 6/6 mRH,BSO,PLA CAP3 dfs(1y7mo) 53.4 
18 51 endometrioid Ib G1 1/6 mRH,BSO,PLA CAP5 dfs(1y5mo) 14 
19 50 endometrioid Ib G2 3/6 mRH,BSO,PLA CAP dfs(1y6mo) 19 
20 50 endometrioid Ib G1 1/6 mRH,BSO,PLA CAP3 dfs(1y7mo) 3.4 
21 54 endometrioid Ib G1 1/6 mRH,BSO,PLA dfs(2y5mo) 0.0 
22 50 endometrioid Ib G1 1/G mRH,BSO,PLA CAP4 dfs(1y10mo) 0.0 
23 74 endometrioid IIIa G1 6/6 ATH,BSO dfs(2y6mo) 16 
24 53 endometrioid Ib G1 1/6 mRH,BSO,PLA dfs(1y6mo) 1.5 
25 47 endometrioid Ib G2 2/6 mRH,BSO,PLA CAP3 dfs(1y6mo) 5.4 
26 60 endometrioid Ib G2 1/6 ARH,PLA CAP3 dfs(1y5mo) 11.1 
27 58 endometrioid Ib G1 1/6 mRH,BSO,PLA dfs(1y5mo) 9 
28 65 endometrioid Ib G1 1/6 mRH,BSO,PLA dfs(1y4mo) 16.4 
29 70 endometrioid IV G3 6/6 probe lapa CAP,TJ death(2y5mo) 31 
30 53 endometrioid Ib G2 4/6 mRH,BSO,PLA CAP dfs(1y4mo) 16.8 
31 61 endometrioid Ib G1 2/6 mRH,BSO,PLA dfs(2y8mo) 16.8 
32 61 endometrioid Ic G1 4/6 ATH,BSO unknown 29 
33 41 complex hyperplasia p 0 ATH,BSO dfs(3y8mo) 1.2 
34 49 endometrioid IIIa G2 3/6 mRH,BSO,PLA CAP dfs(2y6mo) 4.5 
35 41 endometrioid IIb G1 2/6 ARH,BSO,PLA radiation dfs(1y3mo) 5 
36 70 endometrioid Ic G2 1/6 mRH,BSO,PLA dfs(1y3mo) 1.5 
37 50 normal(secretary phase) ATH 14.6 
endometrioid, endometrioid adenocarcinoma; adenosquamous, adenosquamous carcinoma; serous adeno, serous adenocarcinoma; clear cell, clear cell
adenocarcinoma; mRH, modified radical hysterectomy; BSO, bilateral salpingo-oophorectomy; PLA, pelvic lymphadenectomy; PAN, para-aortic
lymphadenectomy; ARH, abdominal radical hysterectomy; CAP, cyclofosphamide-farmorubicin-cisplatin; TJ, paclitaxel-carboplatin; dfs, desease free survival;
pos, postoperative survival; *1Patient died of cerebral infarction, *2Patient died of pulmonary embolism. 548 F Takama et al
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and that both ER-a positive (T-47D, T-47D-5) and negative (MDA
MB231, MCF 10A1) cell lines express ER-b. They suggested that
ER-b expression plays a possible role in human breast cancer.
Leygue et al (1998) used multiplex-PCR and a ligand binding
assay to show that the ER-a:ER-b ratio significantly increases 
in tumour components compared with normal components.
Therefore, this ratio might play a role in the alteration of oestrogen
action that occurs during the development of human breast cancer.
In addition, Speirs et al (1999) showed that most breast tumours
express ER-b, either alone or in combination with ER-a, and that
those tumours coexpressing ER-a and ER-b were node positive
and tended to be of higher grade. Thus, the clinical importance 
of measuring ER-b levels in breast cancer has been established.
However, the relevance to endometrial cancer has not been
determined. 
We are the first to study ER-a and ER-b mRNA coexpression in
human endometrial cancer tissue using multiplex RT-PCR and to
demonstrate a correlation between the ER-b:ER-a ratio and clini-
copathological parameters. We found that ER-a mRNA was
expressed in all endometrial carcinomas examined. While the
expression of ER-b mRNA varied among tumours and the level of
ER-b mRNA was relatively high especially in advanced invasive
carcinomas, the ER-b:ER-a mRNA ratio significantly correlated
with the depth of myometrial invasion. Western blotting analysis
also showed that ER-b proteins were highly expressed in compar-
ison with ER-a proteins in endometrial cancer with severe
myometrial invasion. The depth of myometrial invasion is a potent
risk factor for endometrial cancer and positively correlates with
prognosis (Le Vacchia et al, 1983; Morrow et al, 1991). Therefore,
preoperative knowledge of the precise depth of myometrial
invasion undoubtedly benefits surgical planning. Ultrasound and
MRI imaging or measurement of serum CA125 levels are useful,
but when endometriosis or leiomyoma are complicating factors,
such findings are not sufficient. The results of the present study
demonstrated that understanding the ER-b:ER-a ratio could be
beneficial for predicting the depth of myometrial invasion. 
The mechanisms behind how the expression of ER-b causes
deep endometrial invasion are difficult to define. ER subtypes can
signal not only from the classical oestrogen response element but
also from an AP1 enhancer element (Gaub et al, 1990; Paech et al,
1997). Therefore, ER-b may elicit its own signals and interfere
with those of ER-a. Theoretically, the growth of ER positive cells
can be inhibited by antioestrogens, such as tamoxifen or the pure
antioestrogen, ICI 182780. Tamoxifen is currently the first-line
therapy for treatment of ER positive breast cancer (Osborne et al,
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Figure 1 Multiplex amplification of T1 (moderate ER-b/high ER-a content)
and T2 (low ER-b/high ER-a content) cDNA mixed preparations. (A) Increas-
ing amounts of T1 cDNA and decreasing amounts of T2 cDNA were mixed
and amplified by PCR using ER-a and ER-b specific primers in a single tube.
(B) PCR products were separated on 1.8% metaphor agarose gels and
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1998). However, some patients who initially respond to tamoxifen
eventually go into relapse, probably due to the acquisition of
antioestrogen resistance. ER-b positivity tends to be associated
with more poorly differentiated breast cancers (Speirs et al, 1999)
and it has been shown that ER-b is overexpressed in tamoxifen
resistant breast tumour (Speirs et al, 1999). Therefore, the
coexpression of ER subtypes in the same tumour may modify the
response to oestrogen and the tumour may become deeply invasive
even in a low oestrogen environment. On the other hand, tamox-
ifen acts as an antioestrogenic and as an oestrogen-like substance
on the endometrium (Hyder et al, 1996; Berliere et al, 1998), but
its molecular mechanism has not yet been confirmed. The expres-
sion of ER-a and ER-b may decide the nature of the endometrial
cell response to tamoxifen. 
Many studies have suggested that the progesterone receptor
(PR)/ER concentration is significant as a prognostic parameter for
endometrial cancer (Friberg and Noren, 1993; Kadar et al, 1993;
Morris et al, 1995; Moutsatsou and Sekeris 1997), and that PR status
significantly predicts the disease-free survival of patients with
endometrial cancer. It has been shown that lymph node metastasis
from endometrial cancer is correlated with negative PR protein
expression (Iwai et al, 1999). Therefore, the effect of ER-b on the
expression of PR as well as the mechanism of how ER-b affects the
nature of endometrial cancer should be clarified. Based on our result,
PR protein expression appeared not to be associated with that of ER
subtypes and clinicopathological parameters. Only one sample was
node positive in our study. Thus, this issue needs to be investigated in
studies involving more cases with nodal involvement. 
We reported that ER-b/ER-a expression ratio was useful as 
a novel prognostic indicator. The patients in this study were
followed for a limited duration after operation, and thus whether or
not ER-b status actually indicates disease-free survival must be
established. 
In conclusion, although the biochemical function of ER-b in
relation to endometrial cancer remains unknown, our results
suggest that ER-b plays an important role in the progress of
myometrial invasion. If so, ER-b may be an useful prognostic tool
for patients with endometrial carcinoma. 
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